Early results of avelumab in Hodgkin lymphoma
Avelumab is well tolerated and has shown early evidence of activity against relapsed or refractory Hodgkin lymphoma.
Read the latest news and views from Lymphoma Action.
Use the drop down filter to find the most relevant news for you.
Avelumab is well tolerated and has shown early evidence of activity against relapsed or refractory Hodgkin lymphoma.
Epcoritamab has produced promising results in an early phase clinical trial.
If you have CLL or SLL, let us know your experience of treatment and your views on potential future treatments by taking part in an online survey.
How can I find out about a trial that may be suitable for me?
This year, the British Society for Haematology held their annual scientific meeting online. Clinical experts presented some of the latest developments across all areas of lymphoma research.
Centres in Southampton, Oxford, Portsmouth, Nottingham, Leicester, Norfolk and Newcastle are inviting people with lymphoma to take part in a research study.
Research participants needed for study of lung cancer screening decision-making after Hodgkin lymphoma.
Results of the ZUMA-5 trial show that CAR T-cell therapy has high response rates in relapsed or refractory follicular lymphoma or marginal zone lymphoma.
Study of treatment decisions in Hodgkin lymphoma.
MATRix-RICE chemotherapy followed by a stem cell transplant shows favourable outcomes in people with lymphoma that has spread to the brain or spinal cord.